Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomasHSB-1216 was recently granted...